

## Transparency Guideline for the Relation between Corporate Activity and Medical Institutes

### 1. Purpose

DENIS Pharma K.K. (called DENIS Pharma hereafter), as a member of “Japan Association of Clinical Reagent Manufacturers”(called JACRM hereafter), here establishes “Transparency Guideline for the Relation between Corporate Activity and Medical Institutes” to obtain transparency regarding all activities that DENIS Pharma transacts, in accordance with the spirit of “Code of Ethical Practice for In vitro diagnostics” and “Promotion code for In vitro diagnostics” that JACRM established and also other related rules.

### 2. Disclosure Method

The information should be disclosed on the DENIS Pharma official web site.

### 3. Timing of disclosure

The information of the previous fiscal year should be disclosed since 2015 fiscal year.

### 4. Targets of disclosure

#### A. Research and Development expenses

Research and Development expenses include expenses of clinical studies, clinical performance studies for new products and post-marketing studies, adverse event reaction reporting conducted under public regulations such as the GCP ordinance.

Target	Disclosing item
Joint research expenses	Annual total amount
Research commissioning expenses	Annual total amount

#### B. Academic research support expenses

Scholarship donations and general donations for promotion of academic researchers or research supports, donations to academic societies for supporting conference holding, and expenses of co-sponsored conference with academic society

Target	Disclosing item
Scholarship donation	Number of donations, annual total amount
General donation	Number of donations, annual total amount
Donation to academic society	Number of donations, annual total amount
Expenses of co-sponsored 学会共催費	Number of cases, annual total amount

C. Manuscript/writing fees, etc.

Fee for lectures and manuscript writing, for provision of scientific information, and fee for consulting contracts are included.

Target	Disclosing item
Fee for lecture	Number of cases, annual total amount
Manuscript writing fee/supervising fee	Number of cases, annual total amount
Fee for consulting contracts	Number of cases, annual total amount

D. Information provision-related expenses

Expenses of lecture meeting and explanation meeting for providing product related scientific information, etc., to healthcare professionals

Target	Disclosing item
Lecture meeting expenses	Number of cases, annual total amount
Explanation meeting expenses	Number of cases, annual total amount
Medical and pharmaceutical literatures, etc supply expenses	Annual total amount

E. Other expenses

Expenses for hospitality, etc courtesy

Target	Disclosing item
Expenses for hospitality etc.	Annual total amount

Revised October 01, 2019

Revised October 31, 2016

Issued June 15, 2015

DENIS Pharma K.K.